After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Concert Pharmaceuticals Inc. (CNCE) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.08, or -1.34%, to $5.90. The Concert Pharmaceuticals Inc. has recorded 199 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research.
CNCE belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $5.98 and fluctuated between $6.35 as its day high and $5.86 as its day low. The current market capitalization of Concert Pharmaceuticals Inc. is $265.51M. A total of 0.71 million shares were traded on the day, compared to an average of 395.98K shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, CNCE has seen 1 BUY and 1 SELL insider trades, representing the acquisition of 3,539 and the disposition of 3,539 shares. Over the last 12 months, there were 19 BUYs and 11 SELLs from insiders. Insiders purchased 914,091 shares during that period but sold 55,170.
In the most recent transaction, HUTT PETER BARTON sold 3,539 shares of CNCE for 6.09 per share on Oct 14. After the transaction, the Director now owns 29,488 company shares. In a previous transaction on Jun 06, van Heek Christi bought 10,526 shares at 4.75 per share. CNCE shares that Director owns now total 25,651.
Among the insiders who bought shares, Auchincloss Thomas G acquired of 6,000 shares on Jun 06 at a per-share price of $4.75. This resulted in the Director holding 17,625 shares of CNCE after the transaction. In another insider transaction, ALDRICH RICHARD bought 210,526 shares at $4.75 per share on Jun 06. Company shares held by the Director now total 210,526.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for CNCE in the last 3 months, the mean price target is $17.40 with high estimates of $25.00 and low estimates of $13.00. In terms of 52-week highs and lows, CNCE has a high of $7.37 and a low of $2.57.
As of this writing, CNCE has an earnings estimate of -$0.59 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.52 per share and a lower estimate of -$0.64. The company reported an EPS of -$1.03 in the last quarter, which was -13.20% lower than expectations of -$0.91.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 5 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CNCE is Overweight with a score of 5.00. A total of 5 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.